Pharma BD Deal Intelligence
Watson Pharmaceuticals announced plans to buy Schein Pharmaceutical in a two-step transaction valued at $674 million, creating a company with combined sales of…
Watson completed its $19.50/share tender for ~77.9% of Schein and paid down ~$190M of Schein bank debt, with the back-end merger to close in September 2000.
The Schein acquisition more than doubled Watson's size and lifted full-year 2000 revenue above $1 billion, establishing Watson as a top-tier US generics…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Watson Pharmaceuticals announced a two-step acquisition of Schein Pharmaceutical valued at ~$674M (cash tender at $19.50 plus stock-merger second step). Bayer Corp. and Schein family controlled 74% and tendered. Created a $1.2B generics business. Closed Sep 2000.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Watson Pharmaceuticals (Actavis Inc.) / Schein Pharmaceutical Inc. (this deal) | 2000 | $674M | 65 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Watson Pharmaceuticals (Actavis Inc.) / Arrow Group | 2009 | $1.8B | 85 |
| Watson Pharmaceuticals (Actavis Inc.) / Amarin Development AB (Amarin Corp subsidiary) | 2003 | $150M | 70 |
| Watson Pharmaceuticals (Actavis Inc.) / Andrx Corporation | 2006 | $1.9B | 65 |
| Watson Pharmaceuticals (Actavis Inc.) / Eden Biodesign Limited | 2010 | $15M | 63 |
| Watson Pharmaceuticals (Actavis Inc.) / Andrx Corporation | 2007 | $1.9B | 62 |
← Browse all deals · How we score deals
More: 2000 deals · Watson Pharmaceuticals (Actavis Inc.) deals · Multiple deals